The “Ultimate Triple PET”: 68Ga-DOTATATE, 18F-FDG, and 18F-Fluciclovine PET/CT Findings in a Single Patient With Metastatic Abdominal Carcinoid and Prostate Cancer

A 71-year-old man with a history of carcinoid and prostate adenocarcinoma underwent 68Ga-DOTATATE PET/CT to evaluate new mediastinal lymphadenopathy. The scan revealed new carcinoid metastases, but the mediastinal nodes were not avid. 18F-FDG PET/CT was performed to evaluate for cardiac and mediasti...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2022-02, Vol.47 (2), p.e161-e164
Main Authors: McClenathan, Matthew, Peacock, Justin G.
Format: Article
Language:English
Subjects:
Aged
Carcinoid Tumor
Fluorodeoxyglucose F18
Humans
Male
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Prostatic Neoplasms
Radionuclide Imaging
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 71-year-old man with a history of carcinoid and prostate adenocarcinoma underwent 68Ga-DOTATATE PET/CT to evaluate new mediastinal lymphadenopathy. The scan revealed new carcinoid metastases, but the mediastinal nodes were not avid. 18F-FDG PET/CT was performed to evaluate for cardiac and mediastinal sarcoidosis, revealing a lack of cardiac sarcoidosis, but probable mediastinal sarcoidosis. 18F-Fluciclovine PET/CT was then performed for possible prostate metastases, revealing the patient's known prostate cancer. Three different PET radiopharmaceuticals revealed 3 different processes in a single patient within a 195-day period, demonstrating the power of nuclear medicine diagnostics.
ISSN:0363-9762
1536-0229
DOI:10.1097/RLU.0000000000003853